Twitter | Search | |
Pharmaxis
A pharmaceutical research company with approved products in world markets and a drug discovery program focused on treatments for fibrosis and inflammation.
171
Tweets
167
Following
232
Followers
Tweets
Pharmaxis Aug 4
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Jul 22
Pharmaxis submits Investigational New Drug application for treatment of myelofibrosis via
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Jul 13
Pharmaxis granted orphan drug designation for PXS‐5505 by FDA for treatment of myelofibrosis via
Reply Retweet Like
Pharmaxis May 4
Reply Retweet Like
Pharmaxis Apr 28
Watch CEO Gary Phillips discuss our clinical study investigating a drug to treat the bone marrow cancer myelofibrosis
Reply Retweet Like
Pharmaxis Apr 27
Reply Retweet Like
Pharmaxis Apr 27
Pleased to report we are moving to a phase 2 study of our anti-fibrotic LOX inhibitor drug for treatment of the rare bone cancer myelofibrosis following positive phase 1 and tox studies.
Reply Retweet Like
Pharmaxis retweeted
ASX Bot Jan 30
Pharmaxis advancing anti fibrotic compounds towards phase 2 clinical trials; Bronchitol sales rise with FDA decision expected mid-year
Reply Retweet Like
Pharmaxis retweeted
CommSec Dec 4
[VIDEO] Executive Series: Ltd MD, Gary Phillips speaks about the company’s broad pipeline of drug candidates, large licence deal with Boehringer & upcoming Phase 2 clinical results for NASH
Reply Retweet Like
Pharmaxis retweeted
CommSec Dec 3
[VIDEO] Executive Series: Ltd MD, Gary Phillips speaks about the company’s broad pipeline of drug candidates, large licence deal with Boehringer & upcoming Phase 2 clinical results for NASH
Reply Retweet Like
Pharmaxis Nov 20
CEO Gary Phillips tells the AGM that is a global leader in inflammation and fibrosis with many assets, a strong balance sheet and leadership team. Our work has attracted specialist healthcare investors in the USA and UK.
Reply Retweet Like
Pharmaxis Nov 20
Chairman tells the Pharmaxis AGM how the company is building value with a research pipeline that has delivered four new drugs to the clinic in the past five years.
Reply Retweet Like
Pharmaxis Oct 30
Pharmaxis progressing and considering partners
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Oct 29
Pharmaxis anti-fibrotic pipeline review highlights drug with strong pre-clinical data for bone marrow cancer myelofibrosis via
Reply Retweet Like
Pharmaxis Oct 29
CEO Gary Phillips tells the conference how is advancing drug discovery in the hot area of antifibrotics
Reply Retweet Like
Pharmaxis retweeted
AdAlta Limited Oct 29
Chief Scientific Officer Mick Foley chairing AusBiotech Panel Discussion showing the strength of Australian biotech, "Anti-fibrotic drugs: A hot area for big pharma" with
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Oct 27
Pharmaxis licensee receives US FDA guidance on Bronchitol approval steps via
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Oct 23
Pharmaxis begins dosing patients in phase Ib study via
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Oct 16
Pharmaxis cash funds for development of new drugs boosted by $6.2 million R&D tax incentive via
Reply Retweet Like
Pharmaxis retweeted
Proactive Australia Sep 11
Pharmaxis features in APAC’s top 100 most innovative pharma companies report via
Reply Retweet Like